<DOC>
	<DOCNO>NCT00741234</DOCNO>
	<brief_summary>This open label , dose escalation study 3 arm ( Arms A , B , C ) . Arm A assess safety tolerability escalate dos SB939 cohorts patient advance solid tumor . Arm B ass safety tolerability escalate dos cohorts patient advance hematologic malignancy . Arm C ass safety tolerability SB939 combination standard azacitidine therapy .</brief_summary>
	<brief_title>A Phase I Dose Escalation Study Oral SB939 Administered Alone With Azacitidine</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Inclusion criterion : Arms A &amp; B : Patients solid tumor Arm A hematologic malignancy Arm B classify intermediate 1 great accord International Prognostic Scoring System ( IPSS ) risk category therapy indicate ; ECOG performance status ( PS ) 02 ; Patients must adequate nonhematologic organ system function . Arm C : Patients MDS classify intermediate 1 great accord International Prognostic Scoring System ( IPSS ) risk category therapy indicate ; Have treat azacitidine candidate treatment azacitidine ; ECOG performance status ( PS ) 02 ; Patients must adequate nonhematologic organ system function .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>SB939</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>Combination azacitidine</keyword>
	<keyword>Solid malignancy</keyword>
	<keyword>Hematologic malignancy</keyword>
	<keyword>HDAC inhibitor</keyword>
	<keyword>Refractory standard therapy</keyword>
</DOC>